{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-052008","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.650433+00:00","generated_at":"2026-05-16T20:32:07.097791+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TriSalus Q3 revenue $11.6M (+57% YoY); net loss $41.3M on preferred conversion; reaffirms 50% FY growth","bullets":["Revenue $11.6M, up 57% YoY and 3% sequentially; all from TriNav liver embolization.","Gross margin 84% vs 86% prior year; operating loss $9.0M vs $8.7M.","Net loss attributable to common $41.3M ($0.96 EPS) due to $30.5M preferred conversion charge.","Adjusted EBITDA loss improved to $5.4M from $7.2M; cash $22.7M with runway to positive adj. EBITDA.","Reaffirmed FY2025 revenue growth of at least 50%; initiated GAE trial for knee OA; published thyroid embolization data."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-052008","json":"https://secwatch.observer/filing/0001628280-25-052008.json","markdown":"https://secwatch.observer/filing/0001628280-25-052008.md","text":"https://secwatch.observer/filing/0001628280-25-052008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000162828025052008/0001628280-25-052008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000162828025052008/tlsi-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:32:07.097791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}